Interleukin-1 potently contributes to 25-hydroxycholesterol-induced synergistic cytokine production in smooth muscle cell-monocyte interactions

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 443-452

  Fu, Hang ^a   Spieler, Florian ^a   Großmann, Julia ^a   Riemann, Dagmar ^b   Larisch, Marie ^a   Hiebl, Bernhard ^b   Schlecht, Kathrin ^a   Jaschke, Carolin ^a   Bartling, Babett ^a   Hofmann, Britt ^a   Unverzagt, Susanne ^b   Koch, Susanne ^a   Pilowski, Claudia ^a   Simm, Andreas ^a   Silber, Rolf Edgar ^a   Gielen, Stephan ^a   Seliger, Barbara ^b   Schlitt, Axel ^a   Ebelt, Henning ^a   Müller Werdan, Ursula ^a   Buerke, Michael ^a   Werdan, Karl ^a   Loppnow, Harald ^a   more..

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Atherogenesis; Cell interaction; Cholesterol; Inflammasome; Innate immunity; Interleukin; Monocytes; Smooth muscle cells

Indexed keywords

25 HYDROXYCHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTICLE; CELL ACTIVATION; CELL INTERACTION; CELL ISOLATION; CELLS; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MONOCULTURE; MONOCYTE; MONOCYTE CULTURE; POLYMERASE CHAIN REACTION; PRE B LYMPHOCYTE; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; SUPERNATANT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

EID: 84908552354     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.002     Document Type: Article

References (51)

1. Ross R. Atherosclerosis - an inflammatory disease. N.Engl. J. Med. 1999, 340:115-126.
2. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J.Am. Coll. Cardiol. 2009, 54:2129-2138.
3. Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 2006, 86:515-581.
4. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc. Res. 2008, 79:360-376.
5. Loppnow H., Buerke M., Werdan K., Rose-John S. Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J.Cell. Mol. Med. 2011, 15:484-500.
6. Loppnow H., Werdan K., Buerke M. Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms. Innate Immun. 2008, 14:63-87.
7. Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., Kayal S., Sarnacki S., Cumano A., Lauvau G., Geissmann F. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007, 317:666-670.
8. Grebe A., Latz E. IL-1, quo vadis?. Atherosclerosis 2012, 222:324-325.
9. Chen L., Frister A., Wang S., Ludwig A., Behr H., Pippig P., Li B., Simm A., Hofmann B., Pilowski C., Koch S., Buerke M., Rose-John S., Werdan K., Loppnow H. Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances interleukin-6 and MCP-1 production. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H987-H996.
10. Loppnow H., Zhang L., Buerke M., Lautenschläger M., Chen L., Frister A., Schlitt A., Luther T., Song N., Hofmann B., Rose-John S., Silber R.E., Müller-Werdan U., Werdan K. Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J.Cell. Mol. Med. 2011, 15:994-1004.
11. Johnson K.A., Morrow C.J., Knight G.D., Scallen T.J. Invivo formation of 25-hydroxycholesterol from endogenous cholesterol after a single meal, dietary cholesterol challenge. J.Lipid Res. 1994, 35:2241-2253.
12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
13. Yehuda H., Szuchman-Sapir A., Khatib S., Musa R., Tamir S. Human atherosclerotic plaque lipid extract promotes expression of proinflammatory factors in human monocytes and macrophage-like cells. Atherosclerosis 2011, 218:339-343.
14. Rydberg E.K., Salomonsson L., Hulten L.M., Noren K., Bondjers G., Wiklund O., Bjornheden T., Ohlsson B.G. Hypoxia increases 25-hydroxycholesterol-induced interleukin-8 protein secretion in human macrophages. Atherosclerosis 2003, 170:245-252.
15. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., Abela G.S., Franchi L., Nunez G., Schnurr M., Espevik T., Lien E., Fitzgerald K.A., Rock K.L., Moore K.J., Wright S.D., Hornung V., Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
16. Rajamaki K., Lappalainen J., Oorni K., Valimaki E., Matikainen S., Kovanen P.T., Eklund K.K. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5:e11765.
17. Shemesh S., Kamari Y., Shaish A., Olteanu S., Kandel-Kfir M., Almog T., Grosskopf I., Apte R.N., Harats D. Interleukin-1 receptor type-1 in non-hematopoietic cells is the target for the pro-atherogenic effects of interleukin-1 in apoE-deficient mice. Atherosclerosis 2012, 222:329-336.
18. Loppnow H., Libby P. Adult human vascular endothelial cells express the IL-6 gene differentially in response to LPS or IL-1. Cell. Immunol. 1989, 122:493-503.
19. Loppnow H., Libby P. Proliferating or interleukin-1-activated human vascular smooth muscle cells secrete copious interleukin-6. J.Clin. Invest 1990, 85:731-738.
20. Loppnow H., Stelter F., Schönbeck U., Schlüter C., Ernst M., Schütt C., Flad H.-D. Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14. Infect. Immun. 1995, 63:1020-1026.
21. Kirii H., Niwa T., Yamada Y., Wada H., Saito K., Iwakura Y., Asano M., Moriwaki H., Seishima M. Lack of interleukin-1ß decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:656-660.
22. Kamari Y., Werman-Venkert R., Shaish A., Werman A., Harari A., Gonen A., Voronov E., Grosskopf I., Sharabi Y., Grossman E., Iwakura Y., Dinarello C.A., Apte R.N., Harats D. Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 2007, 195:31-38.
23. Chi H., Messas E., Levine R.A., Graves D.T., Amar S. Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model - pharmacotherapeutic implications. Circulation 2004, 110:1678-1685.
24. Chamberlain J., Evans D., King A., Dewberry R., Dower S., Crossman D., Francis S. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am. J. Pathol. 2006, 168:1396-1403.
25. Ridker P.M., Thuren T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 2011, 162:597-605.
26. Bhaskar V., Yin J., Mirza A.M., Phan D., Vanegas S., Issafras H., Michelson K., Hunter J.J., Kantak S.S. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis invitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis 2011, 216:313-320.
27. Schönbeck U., Herzberg M., Petersen A., Wohlenberg C., Gerdes J., Flad H.-D., Loppnow H. Human vascular smooth muscle cells express interleukin-1beta-converting enzyme (ICE), but inhibit processing of the interleukin-1beta precursor by ICE. J.Exp. Med. 1997, 185:1287-1294.
28. Loppnow H., Brade H., Dürrbaum I., Dinarello C.A., Kusumoto S., Rietschel E.T., Flad H.-D. IL-1 induction capacity of defined lipopolysaccharide partial structures. J.Immunol. 1989, 142:3229-3238.
29. 2-terminal amino acid sequence of a T-cell derived lymphokine with growth factor activity for B-cell hybridomas. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:9679-9683.
30. Dinarello C.A., Ikejima T., Warner S.J.C., Orencole S.F., Lonnemann G., Cannon J.G., Libby P. Interleukin-1 induces interleukin-1. I. Induction of circulating interleukin-1 in rabbits invivo and in human mononuclear cells invitro. J.Immunol. 1987, 139:1902-1910.
31. Loppnow H., Libby P. Functional significance of human vascular smooth muscle cell-derived interleukin-1 in paracrine and autocrine regulation pathways. Exp. Cell. Res. 1992, 198:283-290.
32. Warner S.J.C., Auger K.R., Libby P. Interleukin-1 induces interleukin-1. Recombinant human interleukin-1 induces interleukin-1 production by adult human vascular endothelial cells. J.Immunol. 1987, 139:1911-1917.
33. Westphal E., Herzberg M., Neumann I., Li B., Pilowski C., Chen L., Werdan K., Loppnow H. Neutrophils process IL-1beta and IL-18 precursors in a caspase-1-like fashion - processing is inhibited by human vascular smooth muscle cells. Eur. Cytokine Netw. 2006, 17:19-28.
34. Netea M.G., Nold-Petry C.A., Nold M.F., Joosten L.A., Opitz B., van der Meer J.H., van de Veerdonk F.L., Ferwerda G., Heinhuis B., Devesa I., Funk C.J., Mason R.J., Kullberg B.J., Rubartelli A., van der Meer J.W., Dinarello C.A. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood 2009, 113:2324-2335.
35. Zhu Y., Hojo Y., Ikeda U., Takahashi M., Shimada K. Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase-1 production. J.Cardiovasc Pharmacol. 2000, 36:152-161.
36. Loppnow H., Libby P. Comparative analysis of cytokine induction in human vascular endothelial and smooth muscle cells. Lymphokine Res. 1989, 8:293-299.
37. Tschopp J., Martinon F., Burns K. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell. Biol. 2003, 4:95-104.
38. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13:397-411.
39. Grebe A., Latz E. Cholesterol crystals and inflammation. Curr. Rheumatol. Rep. 2013, 15:313.
40. Garlanda C., Dinarello C.A., Mantovani A. The interleukin-1 family: back to the future. Immunity 2013, 39:1003-1018.
41. Rider P., Carmi Y., Voronov E., Apte R.N. Interleukin-1alpha. Semin. Immunol. 2013, 25:430-438.
42. Harris H.E., Raucci A. Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 2006, 7:774-778.
43. Oppenheim J.J., Yang D. Alarmins: chemotactic activators of immune responses. Curr. Opin. Immunol. 2005, 17:359-365.
44. Wessendorf J.H., Garfinkel S., Zhan X., Brown S., Maciag T. Identification of a nuclear localization sequence within the structure of the human interleukin-1α precursor. J.Biol. Chem. 1993, 268:22100-22104.
45. Kurt-Jones E.A., Beller D.I., Mizel S.B., Unanue E.R. Identification of a membrane-associated interleukin-1 in macrophages. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:1204-1208.
46. Martinon F. Detection of immune danger signals by NALP3. J.Leukoc. Biol. 2008, 83:507-511.
47. Pearson J.D., Gordon J.L. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature 1979, 281:384-386.
48. Lohman A.W., Billaud M., Isakson B.E. Mechanisms of ATP release and signalling in the blood vessel wall. Cardiovasc. Res. 2012, 95:269-280.
49. Kurashima Y., Amiya T., Fujisawa K., Shibata N., Suzuki Y., Kogure Y., Hashimoto E., Otsuka A., Kabashima K., Sato S., Sato T., Kubo M., Akira S., Miyake K., Kunisawa J., Kiyono H. The enzyme cyp26b1 mediates inhibition of mast cell activation by fibroblasts to maintain skin-barrier homeostasis. Immunity 2014, 40:530-541.
50. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
51. Libby P., Ordovas J.M., Birinyi L.K., Auger K.S., Dinarello C.A. Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J.Clin. Invest 1986, 78:1432-1438.